한글목차

키트루다는 PD-1 또는 PD-L1에 결합하여 PD-1/PD-L1 경로를 차단하여 면역 반응의 억제를 해제하고 말초 관용을 파괴하여 면역 매개 부작용을 유발할 수 있는 단일 클론 항체입니다. 미국 FDA는 이미 키트루다를 흑색종, 비소세포폐암, 재발성 또는 전이성 두경부암, 고전적 호지킨림프종, 요로상피암 등 특정 유형의 암 치료제로 승인한 바 있습니다. 현재 난소암 치료제로도 검토 중입니다.

현재 난소암 치료제로서 3상 임상시험이 진행 중입니다. 키트루다는 이미 다양한 종양 유형에서 매우 좋은 결과를 얻었으므로, 회사는 다양한 환자군에서 이 약물의 효능과 안전성을 검증하기 위해 다양한 시험을 진행하고 있습니다.

앞으로 몇 년동안 난소암 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, 키트루다의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 난소암에 대한 다른 신흥 제품들이 키트루다와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 난소암 치료제 키트루다 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 난소암 치료제 키트루다 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 키트루다 시장 평가

• 난소암 치ㄹ제 키트루다 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 난소암 치료제 키트루다 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed picture of the KEYTRUDA for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the KEYTRUDA for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KEYTRUDA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the PD-1 or the PD-L1, blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. The US FDA has already approved KEYTRUDA for the treatment of certain types of cancers, including melanoma, non-small cell lung cancer, recurrent or metastatic head and neck cancer, classical Hodgkin lymphoma, and urothelial carcinoma. The drug is still under investigation for the treatment of ovarian cancer.

The drug is currently being developed in Phase III for the treatment of ovarian cancer. As KEYTRUDA is already established and very well performing in different tumor types, the company is running various trials to test this drug's efficacy and safety in different patient segments in different trials.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the KEYTRUDA description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on KEYTRUDA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KEYTRUDA research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around KEYTRUDA.
• The report contains forecasted sales of KEYTRUDA for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for KEYTRUDA in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KEYTRUDA Analytical Perspective by DelveInsight

• In-depth KEYTRUDA Market Assessment

This report provides a detailed market assessment of KEYTRUDA for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• KEYTRUDA Clinical Assessment

The report provides the clinical trials information of KEYTRUDA for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KEYTRUDA dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to KEYTRUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KEYTRUDA in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of KEYTRUDA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KEYTRUDA in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of KEYTRUDA?
• What is the clinical trial status of the study related to KEYTRUDA in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KEYTRUDA development?
• What are the key designations that have been granted to KEYTRUDA for ovarian cancer?
• What is the forecasted market scenario of KEYTRUDA for ovarian cancer?
• What are the forecasted sales of KEYTRUDA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to KEYTRUDA for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. KEYTRUDA Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. KEYTRUDA Market Assessment

• 5.1. Market Outlook of KEYTRUDA in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of KEYTRUDA in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of KEYTRUDA in the United States for ovarian cancer
  • 5.3.2. Market Size of KEYTRUDA in Germany for ovarian cancer
  • 5.3.3. Market Size of KEYTRUDA in France for ovarian cancer
  • 5.3.4. Market Size of KEYTRUDA in Italy for ovarian cancer
  • 5.3.5. Market Size of KEYTRUDA in Spain for ovarian cancer
  • 5.3.6. Market Size of KEYTRUDA in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of KEYTRUDA in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options